Elevating the horizon: Emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma Journal Article
| Authors: | Kurtoglu, M.; Davarpanah, N. N.; Qin, R.; Powles, T.; Rosenberg, J. E.; Apolo, A. B. |
| Article Title: | Elevating the horizon: Emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma |
| Abstract: | Despite recent advances in the identification of genomic alterations that lead to urothelial oncogenesis in vitro, patients with advanced urothelial carcinomas continue to have poor clinical outcomes. In the present review, we focus on targeted therapies that have yielded the most promising results alone or combined with traditional chemotherapy, including the antiangiogenesis agent bevacizumab, the human epidermal growth factor receptor 2 antibody trastuzumab, and the tyrosine kinase inhibitor cabozantinib. We also describe ongoing and developing clinical trials that use innovative approaches, including dose-dense scheduling of singular chemotherapy combinations, prospective screening of tumor tissues for mutational targets and biomarkers to predict chemosensitivity before the determination of the therapeutic regimen, and novel agents that target proteins in the immune checkpoint regulation pathway (programmed cell death protein 1 [PD-1] and anti-PD-ligand 1) that have shown significant potential in preclinical models and early clinical trials. New agents and targeted therapies, alone or combined with traditional chemotherapy, will only be validated through accrual to developing clinical trials that aim to translate these therapies into individualized treatments and improved survival rates in urothelial carcinoma. © 2015 Elsevier Inc. All rights reserved. |
| Keywords: | cancer survival; unclassified drug; drug tolerability; review; sorafenib; angiogenesis inhibitor; bevacizumab; cisplatin; advanced cancer; cancer combination chemotherapy; drug efficacy; paclitaxel; cancer adjuvant therapy; neoplasm; chemosensitivity; bladder cancer; carcinogenesis; cancer resistance; pazopanib; targeted therapy; trastuzumab; nilotinib; transitional cell carcinoma; everolimus; rapamycin; lapatinib; epidermal growth factor receptor antibody; clinical trials; clinical trial (topic); molecularly targeted therapy; mocetinostat; novel agents; cabozantinib; dovitinib; dose densification; buparlisib; immune checkpoints; human; nintedanib; binimetinib; checkpoint kinase inhibitor; alt 801; alpelisib; ribociclib; 4 amino n [1 (4 chlorophenyl) 3 hydroxypropyl] 1 (7h pyrrolo[2,3 d]pyrimidin 4 yl) 4 piperidinecarboxamide; azd 8835; bay 1163877; fpa 144; gsk 3052230; infigratinib; mln 1117; mm 141 |
| Journal Title: | Clinical Genitourinary Cancer |
| Volume: | 13 |
| Issue: | 5 |
| ISSN: | 1558-7673 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-10-01 |
| Start Page: | 410 |
| End Page: | 420 |
| Language: | English |
| DOI: | 10.1016/j.clgc.2015.02.009 |
| PROVIDER: | scopus |
| PMCID: | PMC4561017 |
| PUBMED: | 25862322 |
| DOI/URL: | |
| Notes: | Export Date: 2 October 2015 -- Source: Scopus |
